Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fathi

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2021
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyPatrick A Brown, Bijal Shah, Anjali Advani, et al.
Cancer Cell|June 13, 2020
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionRui Su, Lei Dong, Yangchan Li, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2021
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyPatrick A Brown, Bijal Shah, Anjali Advani, et al.
Cancer Cell|June 13, 2020
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionRui Su, Lei Dong, Yangchan Li, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Pageof 17